- Home
- Publications
- Publication Search
- Publication Details
Title
The use of eculizumab in renal transplantation
Authors
Keywords
-
Journal
CLINICAL TRANSPLANTATION
Volume 27, Issue 3, Pages E216-E229
Publisher
Wiley
Online
2013-03-21
DOI
10.1111/ctr.12102
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical Grand Rounds: Atypical Hemolytic Uremic Syndrome
- (2012) Kavita S. Hodgkins et al. AMERICAN JOURNAL OF NEPHROLOGY
- Antibody Mediated Rejection Associated With Complement Factor H-Related Protein 3/1 Deficiency Successfully Treated With Eculizumab
- (2012) D. Noone et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Recurrent Dense Deposit Disease After Renal Transplantation: An Emerging Role for Complementary Therapies
- (2012) J. A. McCaughan et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Renal Transplantation Under Prophylactic Eculizumab in Atypical Hemolytic Uremic Syndrome With CFH/CFHR1 Hybrid Protein
- (2012) S. Krid et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Eculizumab for Atypical Hemolytic Uremic Syndrome Recurrence in Renal Transplantation
- (2012) J. Zuber et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Multiple Hyperacute Rejections in the Absence of Detectable Complement Activation in a Patient With Endothelial Cell Reactive Antibody
- (2012) A. M. Jackson et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Eculizumab for Dense Deposit Disease and C3 Glomerulonephritis
- (2012) A. S. Bomback et al. Clinical Journal of the American Society of Nephrology
- Eculizumab in Acute Recurrence of Thrombotic Microangiopathy After Renal Transplantation
- (2011) K. Hadaya et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Terminal Complement Inhibition Decreases Antibody-Mediated Rejection in Sensitized Renal Transplant Recipients
- (2011) M. D. Stegall et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Pre-emptive Eculizumab and Plasmapheresis for Renal Transplant in Atypical Hemolytic Uremic Syndrome
- (2011) C. Nester et al. Clinical Journal of the American Society of Nephrology
- Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy
- (2011) Antonia Bouts et al. PEDIATRIC NEPHROLOGY
- Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome
- (2011) Marcus Weitz et al. PEDIATRIC NEPHROLOGY
- Immunogenicity of meningococcus C vaccination in a patient with atypical hemolytic uremic syndrome (aHUS) on eculizumab therapy
- (2011) Manuela Zlamy et al. PEDIATRIC TRANSPLANTATION
- Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation
- (2011) Ali-Reza Biglarnia et al. TRANSPLANT INTERNATIONAL
- Successful Treatment of De Novo Posttransplant Thrombotic Microangiopathy With Eculizumab
- (2011) Colin H. Wilson et al. TRANSPLANTATION
- Eculizumab for the Treatment of De Novo Thrombotic Microangiopathy Post Simultaneous Pancreas-Kidney Transplantation—A Case Report
- (2011) S. Chandran et al. TRANSPLANTATION PROCEEDINGS
- Eculizumab, Bortezomib and Kidney Paired Donation Facilitate Transplantation of a Highly Sensitized Patient Without Vascular Access
- (2010) B. E. Lonze et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Complement in organ transplantation
- (2010) Elham Asgari et al. Current Opinion in Organ Transplantation
- 33-OR: Decreased Early Acute Humoral Rejection in Renal Transplant Patients Following Terminal Complement Inhibition
- (2010) Manish J. Gandhi et al. HUMAN IMMUNOLOGY
- Atypical HUS: current diagnostic and therapeutic approaches
- (2010) Alejandra Rosales et al. Nature Reviews Nephrology
- Prophylactic Eculizumab after Renal Transplantation in Atypical Hemolytic–Uremic Syndrome
- (2010) Lothar Bernd Zimmerhackl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Eculizumab and Renal Transplantation in a Patient with CAPS
- (2010) Bonnie E. Lonze et al. NEW ENGLAND JOURNAL OF MEDICINE
- Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation
- (2010) Samhar I. Al-Akash et al. PEDIATRIC NEPHROLOGY
- Efficacy of Eculizumab in the Treatment of Recurrent Atypical Hemolytic-Uremic Syndrome After Renal Transplantation
- (2010) Carlos Fernández-de Larrea et al. TRANSPLANTATION
- Eculizumab: Safety and Efficacy After 17 Months of Treatment in a Renal Transplant Patient With Recurrent Atypical Hemolytic-Uremic Syndrome: Case Report
- (2010) V. Châtelet et al. TRANSPLANTATION PROCEEDINGS
- Maintenance of Kidney Function Following Treatment With Eculizumab and Discontinuation of Plasma Exchange After a Third Kidney Transplant for Atypical Hemolytic Uremic Syndrome Associated With a CFH Mutation
- (2009) Jean-Claude Davin et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Safety and Long-Term Efficacy of Eculizumab in a Renal Transplant Patient with Recurrent Atypical Hemolytic-Uremic Syndrome
- (2009) AMERICAN JOURNAL OF TRANSPLANTATION
- Eculizumab for Atypical Hemolytic–Uremic Syndrome
- (2009) Jens Nürnberger et al. NEW ENGLAND JOURNAL OF MEDICINE
- C5 Blockade with Conventional Immunosuppression Induces Long-Term Graft Survival in Presensitized Recipients
- (2008) R. P. Rother et al. AMERICAN JOURNAL OF TRANSPLANTATION
- The Use of Antibody to Complement Protein C5 for Salvage Treatment of Severe Antibody-Mediated Rejection
- (2008) J. E. Locke et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Complement activation in patients with primary antiphospholipid syndrome
- (2008) K Oku et al. ANNALS OF THE RHEUMATIC DISEASES
- FDA Report: Eculizumab (Soliris(R)) for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria
- (2008) A. Dmytrijuk et al. ONCOLOGIST
- Complement and Renal Transplantation: From Donor to Recipient
- (2008) Jeffrey Damman et al. TRANSPLANTATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More